论文部分内容阅读
在中国加入WTO、医药领域进一步开放、经济全球化进程加快的背景下,中国医药产业将面临大分化、大重组、大洗牌的机遇和挑战。面对世界医药产业的市场、产业结构和企业结构巨大变化,中国医药企业如何提升“软实力”,构建创新能力体系已是当务之急。在调查中记者发现,深化ERP应用,上线在线管理特别是MES成为医药企业支撑创新发展的新抓手。
With China’s accession to the WTO, the pharmaceutical sector further opening up and the process of economic globalization accelerating, the Chinese pharmaceutical industry will face the opportunities and challenges of greater divisions, major restructuring and major reshuffle. The face of the pharmaceutical industry in the world market, the huge changes in industrial structure and enterprise structure, how to enhance the “soft power” of Chinese pharmaceutical companies, building a system of innovative capabilities is the top priority. In the survey, reporters found that deepening the application of ERP, on-line online management, especially MES, has become the new starting point for pharmaceutical companies to support innovation and development.